The debate over FACT accreditation standards for CAR T-cell delivery has sparked a discussion about the need for regulatory bodies to protect patients and ensure safe therapy delivery. Dr. Graff acknowledges the importance of such regulations, but argues that the current standards are outdated and no longer reflect the advancements made in the field since their establishment.
FACT accreditation originated in the bone marrow transplant era, when rigorous guidelines were essential due to the high risks involved. However, with the launch of the first CAR-T products in 2017, toxicities were high and poorly understood, even at experienced centers, which justified strict documentation and oversight.
Evolution of CAR T-Cell Therapy
Nearly a decade later, Dr. Graff notes that CRS and neurotoxicity rates have fallen significantly, mirroring what clinicians see with bispecific antibodies, aided by prophylactic medications and years of accumulated experience. She argues that practices like hers, which have safely managed bispecific antibody toxicities outpatient for four years without yet treating a CAR-T patient, deserve credit for that demonstrated capability.
Related: Rural Patients Face Gaps in Hospice Access and Care
Dr. Graff argues that FACT would deny accreditation to a site whose cellular therapy team has already managed CRS and neurotoxicity in every form, when a CAR-T product would present nothing fundamentally different. This is a constant, daily fight: physicians within the Community Oncology Alliance are continually working to educate payers that accreditation requirements built for an earlier, riskier era should evolve alongside the therapies, the physicians, and the education supporting them.
Access to CAR T-Cell Therapy
The stakes are significant, with only about 20% of patients who need these therapies currently receiving them. Depending on how advanced their disease is, that gap in access can fundamentally change a patient’s life expectancy. Dr. Graff is careful to note that she isn’t singling out FACT itself as the problem; rather, she believes the standards it set years ago haven’t kept pace with how far the field has come.
According to the report, Dr. Porter argues that FACT accreditation’s original rationale for CAR T-cell therapy still holds, even as the standards evolve to fit community programs. The debate highlights the need for ongoing evaluation and adaptation of regulatory standards to ensure that patients receive access to the latest advancements in CAR T-cell therapy.
Related: Considerations To Know About Jungle boys menu
Future of CAR T-Cell Therapy Accreditation
As the field of CAR T-cell therapy continues to advance, The National Cancer Institute provides resources and information on cancer treatment through its website.
FACT accreditation standards for CAR T-cell delivery will likely continue to be a topic of discussion in the medical community, with experts weighing in on the need for evolution and adaptation in regulatory standards. As the stakes are high, with patient lives and life expectancy hanging in the balance, it’s essential that the debate remains focused on finding solutions that prioritize patient access to effective treatments.
They must prioritize patient access.
